← Back to Search

TASCCI for Kidney Failure (TASCCI Trial)

N/A
Waitlist Available
Led By Manisha Jhamb, MD
Research Sponsored by University of Pittsburgh
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
18 years or older
undergoing thrice-weekly maintenance hemodialysis for > 3 months
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 3 month, 6 month, 12 month
Awards & highlights

TASCCI Trial Summary

This trial is testing whether a collaborative care intervention can help reduce symptoms like depression, fatigue, and pain, as well as improve quality of life, for patients undergoing hemodialysis.

Eligible Conditions
  • Kidney Failure
  • Hemodialysis

TASCCI Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

TASCCI Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 3 month, 6 month, 12 month
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 3 month, 6 month, 12 month for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in depression from baseline to 12 weeks
Change in fatigue from baseline to 12 weeks
Change in pain from baseline to 12 weeks
Secondary outcome measures
Change in adherence to fluid restriction
Change in adherence to hemodialysis treatments
Change in adherence to medications
Other outcome measures
To explore effect of TASCCI (hs-CRP, IL-6, IL-10 and TNF-α) on biomarkers of inflammation

TASCCI Trial Design

2Treatment groups
Experimental Treatment
Group I: Technology Delivered Health EducationExperimental Treatment1 Intervention
Patients randomized to the Technology Delivered Health Education Intervention health education group will receive technology delivered health education material on topics relevant to dialysis.
Group II: TASCCIExperimental Treatment1 Intervention
Patients randomized to TASCCI will receive a stepped-care approach of pharmaco and/or behavioral therapy for 12 weeks. The intervention will target 1 or more symptoms based on patients' report of clinical levels of each symptom and patient preference.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
TASCCI
2018
N/A
~160

Find a Location

Who is running the clinical trial?

University of PittsburghLead Sponsor
1,715 Previous Clinical Trials
16,346,671 Total Patients Enrolled
2 Trials studying Kidney Failure
11 Patients Enrolled for Kidney Failure
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,339 Previous Clinical Trials
4,313,669 Total Patients Enrolled
10 Trials studying Kidney Failure
10,720 Patients Enrolled for Kidney Failure
University of New MexicoOTHER
371 Previous Clinical Trials
3,528,881 Total Patients Enrolled
1 Trials studying Kidney Failure
50 Patients Enrolled for Kidney Failure

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~23 spots leftby Mar 2025